Review Article
Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
Table 5
Relative risk reductions (RRRs) of safety outcome event rates versus VKA control groups.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
RRR: relative risk reduction. * P < 0.05. **In modified intention-to-treat analysis, statistical significance was not reported. #Comparison was made using reported raw event frequencies, as annualised event rates were not available. |